The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of L-BLP25 in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.
Carl Christoph Schimanski
Consultant or Advisory Role - Merck Serono
Honoraria - Payment for Speeches
Markus Hermann Moehler
Honoraria - Merck Serono
Hauke Lang
No relevant relationships to disclose
Michael Schoen
No relevant relationships to disclose
Victoria Smith-Machnow
No relevant relationships to disclose
Stephan Kanzler
No relevant relationships to disclose
Susanna Hegewisch-Becker
No relevant relationships to disclose
Steffen Doerfel
No relevant relationships to disclose
Daniel Seehofer
No relevant relationships to disclose
Wolf Bechstein
No relevant relationships to disclose
Michael Heike
No relevant relationships to disclose
Friedrich Overkamp
No relevant relationships to disclose
Frank Kullmann
No relevant relationships to disclose
Matthias Voehringer
No relevant relationships to disclose
Volker Heinemann
No relevant relationships to disclose
Goetz von Wichert
No relevant relationships to disclose
Stefan Kasper
No relevant relationships to disclose
Richard Greil
No relevant relationships to disclose
Hellmut Samonigg
No relevant relationships to disclose
Peter Robert Galle
No relevant relationships to disclose